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Abstract: The goal of postmenopausal hormone therapy is to alleviate the symptoms that are 
associated with the loss of estrogen. Many formulations of estrogen and progestin are available, 
depending on the needs and circumstances of each individual woman. For postmenopausal 
women, the choice of whether or not to begin therapy requires knowledge of the risks and 
beneﬁ  ts of estrogen and/or progestin replacement. The purpose of this review is to describe the 
risks and beneﬁ  ts of hormonal therapy, focusing on estradiol/norethindrone acetate combina-
tion therapy.
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The ﬁ  rst reported use of hormonal therapy to alleviate hot ﬂ  ashes was reported in 
1897 (Fosbery et al 1897). This was accomplished by administering ovarian extract 
to postmenopausal women. Synthetic estrogens were made available in the 1930s 
in the form of stilbestrol and ethinyl estradiol. Estradiol was isolated in 1936, but 
unfortunately, it took 4 tonnes of sows’ ovaries to isolate 12 mg of hormone. Isolat-
ing progesterone proved equally challenging. In 1934 crystalline progesterone was 
isolated from the corpora lutea of 50,000 pigs by Drs. George W Corner and Willard 
Myron Allen (Speroff et al 2005).
Hormone replacement therapy became common in the United States and Europe 
in the 1960s, mainly in the form of ethinyl estradiol. The decline of use in the 1970s 
was attributed to the increased risk of endometrial cancer secondary to unopposed 
estrogen. Progestins were added in the 1980s, which decreased the incidence of 
endometrial cancer and subsequently increased postmenopausal hormonal therapy 
use (Stahlberg et al 2003). In the 1990s, it was well established that postmenopausal 
estrogen therapy prevented osteoporosis, and observational studies suggested that 
estrogen may prevent the development of cardiovascular and Alzheimer’s disease. By 
the late 1990s, 25% of all US women over the age of 40 used hormonal therapy (Brett 
et al 2003). In 2002, the Heart and Estrogen/Progestin Replacement Study (HERS II), a 
randomized controlled clinical trial, reported no cardiovascular beneﬁ  t to women with 
established heart disease while taking combined estrogen and progestin therapy (Grady 
et al 2002). Following this, the randomized controlled clinical trial Women’s Health 
Initiative (WHI) reported a higher incidence of both breast cancer and cardiovascular 
events in women taking combined conjugated estrogen and medroxyprogesterone 
therapy (Rossouw et al 2002). The second arm of the WHI, which evaluated unop-
posed estrogen for women with previous hysterectomies, was discontinued in 2004 
secondary to observance of an increased risk of stroke and lack of protection against 
cardiovascular disease. The Food and Drug Administration (FDA) responded to 
these studies by changing the labeling for postmenopausal hormone therapy, limiting Clinical Interventions in Aging 2008:3(1) 10
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the indications for therapy to reducing the occurrence of 
menopausal symptoms and osteoporosis (Hing and Brett 
2006). Over the next 2 years, the number of women 40 and 
older requesting hormone therapy declined signiﬁ  cantly, as 
the number of visits resulting in a prescription for hormone 
therapy prescribed decreased from 26.5 million in 2001 to 
16.9 million in 2003 (Hing and Brett 2006). Recently, a task 
force has been established by Charles Hammond, MD, of 
the American College of Obstetricians and Gynecologists 
(ACOG) to evaluate the risks and beneﬁ  ts of hormone therapy 
(Table 1) (Executive Summary 2004).
The combination of ethinyl estradiol and norethindrone 
acetate has been used for both oral contraception and post-
menopausal hormonal therapy. In general, these hormones 
mimic the natural hormones estrogen and progesterone, 
respectively. These steroids bind to their receptor, activating 
hormone response elements and gene transcription; this sub-
sequently activates hormone response proteins that inﬂ  uence 
cell function and differentiation (Clark et al 2002).
Pharmacology
The source of estrogen in cycling women is the ovarian 
follicle, which secretes 70–500 µg depending on the phase 
of the cycle. In postmenopausal women, androstendione, 
a hormone produced in the adrenal gland, is converted 
peripherally into estrone and can be conjugated to form 
estrone sulfate. These estrogens are biologically active and 
are similar to ethinyl estradiol.
Table 1 Beneﬁ  ts/risks of hormone therapy: 2004 Executive Summary (ACOG)
Beneﬁ  ts  Comment  Relative risk: based on conjugated 
   estrogen (CEE)/medroxyprogesterone
   (MPA) vs placebo of WHI
Vasomotor symptoms  Estrogens most effective treatment  N/A
Sexual dysfunction  Estrogens effective in relieving atrophy  N/A
 and  dyspareunia
Skin  Increased collagen content and wrinkle   N/A
  reduction (non-sun-exposed areas
Genitourinary tract  Reduces atrophic vaginitis  N/A
Depression  Estrogen may have antidepressant effects  N/A
Colorectal cancer    0.56 (0.38–0.81)
Osteoporosis  Estrogens are effective antiresorptive agents  0.76 (0.69–0.83)a
  and improves bone density
Risks  
Breast cancer  20 per 10,000 risk over 5 years if use combined  1.24 (1.01–1.54)
  estrogen/progestin therapy, no increased risk
  with estrogen therapy alone
Coronary heart disease  Age:
 50–59  1.27  (0.75–2.20)
 60–69  1.05  (0.70–1.80)
 70–79  1.44  (0.90–2.00)
  Years since menopause:
   10 0.89  (0.50–1.50)
 10–19  1.22  (0.80–1.80)
 20+ 1.71  (1.20–2.50)
Thromboembolic disease  2-fold greater risk with increased risk of PE,  DVT: 1.95 (1.43–2.67)
  highest risk during ﬁ  rst year of use  PE: 2.13 (1.45–3.11)
Stroke  Randomized controlled trials show increased risk  1.31 (1.02–1.68)
Cognition  Women’s Health Initiative Memory Study  2.05 (1.21–3.48)
  (WHIMS) – sbset of WHI, found increased
  risk of probable dementia
Neutral  
Weight changes/insulin  No changes, glycemic control in type 2 diabetes  N/A
resistance unchanged  by  hormonal  therapy
Osteoarthritis   N/A
Ovarian and endometrial cancer    Ovarian: 1.58 (0.77–3.24)
    Endometrial: 0.81 (0.48–1.36)
anumber of total fractures, including hip, vertebral and lower arm/wrist.
Abbreviations: PE, pulmonary embolism; DVT, deep vein thrombosis.Clinical Interventions in Aging 2008:3(1) 11
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Progesterone opposes estrogens by decreasing estrogen 
receptors. In the endometrium, progesterone binds to its 
receptor, dimerizes, and binds to progesterone response 
elements. This, in turn, induces gene transcription thus 
activating the secretory phase.
Estradiol is the main estrogen that is secreted by the 
ovaries, and is the most potent. It is inactive if administered 
orally. In 1938 it was discovered that adding an ethinyl 
group at the 17 position of the steroid molecule made the 
hormone orally active. Equally important was the discovery 
of norethindrone in 1951, which is derived from the 
androgen ethisterone. Norethindrone is formed by removing 
the 19-carbon from the ethisterone, thereby changing the 
effect from an androgen to a progestin (Speroff and Fritz 
2005).
Ninety-eight percent of estradiol and norethindrone 
components circulate bound to sex hormone binding 
globulin and albumin. Approximately 2% of estradiol and 
norethindrone circulates unbound in its free form. Peak 
plasma estrogen levels are reached within 5–8 hours of oral 
administration. After oral administration, norethindrone 
acetate is quickly deacylated to norethindrone and reaches a 
peak plasma level within 0.5–1.5 hours. Steady state levels 
of estradiol, estrone, and norethindrone are reached after 
2 weeks of daily administration. The half-life of estradiol 
after a single dose is 12–14 hours, and the terminal half-life 
of norethindrone sulfate is 8–11 hours. Both norethindrone 
and estradiol are subject to ﬁ  rst past metabolism, and retain 
65% and 55% of their bioavailability, respectively.
When taken orally, estradiol is metabolized to mostly 
estrone sulfate. In the liver, estradiol is converted to other 
active metabolites, including estrone and estriol. Estrogens 
undergo sulfate and glucorunide conjugation in the liver 
and are recirculated in these forms. Hydrolysis of estrogen 
occurs in the intestine with subsequent reabsorption. Estra-
diol, estrone, and estriol are all excreted into the urinary 
system.
The norethindrone metabolites 5α-dihydro-norethindrone 
and tetrahydro-norethindrone undergo sulfate or gluconate 
conjugation and are excreted into the urine.
Current preparations 
of combination estradiol (E2)/
norethindrone acetate (NETA)
Activella® (Novo Nordisk Inc., Princeton, NJ, USA) contains 
a combination of estradiol and norethindrone acetate avail-
able in tablet form. It is available in two doses (1 mg/0.5 mg, 
0.5 mg/0.1 mg) and is taken once daily.
Combipatch® (Novartis, Miami, FL, USA) is an adhesive 
patch that contains both estradiol and norethindrone acetate 
and provides a continuous release of both hormones. 
It is available in two doses, either 0.05 mg/0.14 mg or 
0.05/0.25 mg per day.
femhrt® (Duramed Pharmaceuticals, Pomona, NY, USA) 
is an oral hormone alternative that contains norethindrone 
acetate and ethinyl estradiol. It is available in two doses 
(0.5 mg/2.5 µg or 1 mg/5 µg).
Clinical indications
The indications for postmenopausal E2/NETA hormone 
therapy include treatment of severe vasomotor symptoms 
and prevention of postmenopausal osteoporosis. Current 
guidelines by the FDA recommend therapy at the lowest 
effective dose and shortest duration as possible.
Vasomotor symptoms
A 12-week randomized placebo-controlled trial showed that 
E2/NETA signiﬁ  cantly decreased hot ﬂ  ushes at weeks 4 and 
12. At the conclusion of this study, 85% of women receiving 
E2/0.5 mg NETA and 71% of the women receiving E2/0.25 mg 
reported adequate relief of moderate to severe hot ﬂ  ushes 
(Bauerug et al 1998).
Gambacciani et al investigated the effect of daily E2/
NETA and its effect on quality of life in early postmenopausal 
women and found a signiﬁ  cant decrease in severity of hot 
ﬂ  ushes, anxiety/fear, depressed mood and sleep problems 
compared to placebo (Gambacciani et al 2003).
Adler at al investigated both patient and physician satis-
faction with the transdermal 17β-estradiol plus norethindrone 
acetate therapy and found a signiﬁ  cant reduction in the mean 
daily number of moderate-to-severe hot ﬂ  ashes experienced 
by women after 12 weeks of use from 4.1 at week 1 to 0.6 
at week 12 (p   0.0001). They also found that headache 
severity, insomnia, and vaginal irritation/dryness improved 
signiﬁ  cantly by week 6 and were maintained at week 12. 
After 12 weeks of therapy, 92.4% of the subjects and 97.3% 
of the physicians reported that they were 'satisﬁ  ed' or 'very 
satisﬁ  ed' with the transdermal hormone delivery system 
(Adler et al 2005).
A randomized, double-blind multicenter study evalu-
ated 625 postmenopausal women with 3 doses of combined 
transdermal E2/NETA compared to unopposed E2. Intensity 
of hot ﬂ  ashes was graded as 0 (none), 1 (mild), 2 (moderate) 
and 3 (severe) and prior to and after 12 months of treatment 
(Table 2. Hot ﬂ  ushes were decreased in all groups (Archer 
et al 1999).Clinical Interventions in Aging 2008:3(1) 12
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Bone mineral density
Bone resorption is the ﬁ  rst process to occur after menopause 
and the secondary to estrogen deﬁ  ciency. In the 1980s, 
studies linked E2/NETA to increased forearm bone mass 
(Christiansen et al 1980, 1981). It is likely that both E2 
and NETA contribute positively to increased bone mass 
in postmenopausal women. A 2-year randomized, double-
blind, placebo-controlled trial looked at varying doses of 
E2/NETA on postmenopausal women and found that bone 
mineral density increased by 4.8% and 5.4% with higher 
doses of NETA (0.5 mg vs 1.0 mg daily) along with 1 mg E2 
(McClung 1998). Roux et al performed a 2-year randomized 
comparing tibolone and E2/NETA for preventing bone loss in 
postmenopausal women and found that each medication was 
effective. E2/NETA showed an increase in lumbar spine bone 
mineral density of 6.8% ± 4.5% after 2 years of therapy (Roux 
et al 2002). Popp et al found similar results when treating 
postmenopausal women with E2/NETA, with an increase 
in lumbar spine of 3.8% ± 0.6% (Popp et al 2006). Similar 
results have been found by other investigators (Table 3) 
(Arabi et al 2003). E2/NETA in combination is beneﬁ  cial for 
women with established osteoporosis. Women with previous 
osteoporotic fractures participated in a double – blind study of 
2 mg E2/1 mg NETA or placebo. After 12 months of therapy, 
lumbar spine density had increased by 8%–10% and total 
skeleton and distal forearm increased by 3%–5% compared 
with placebo (Christiansen et al 1990).
Ravn et al compared the effects of alendronate, a bisphos-
phanate to sequential E2/NETA (2 mg E2 daily + 1 mg NETA 
for 10 days monthly). After 2 years of treatment, HT led to a 
signiﬁ  cantly greater increase in bone mineral density in the 
spine, hip and total body. Table 4 summarizes the results 
(Ravn et al 1999).
Risks
Endometrial hyperplasia
Several studies have evaluated the protective effects of 
NETA on estrogen-induced hyperplasia in postmenopausal 
women.
A randomized controlled clinical trial was performed 
comparing placebo, unopposed estrogen and combined E2/
NETA with different doses of NETA. A signiﬁ  cant decrease 
in endometrial hyperplasia was found in patients receiving 
combination E2/NETA therapy compared to estrogen only 
treatment (Table 5) (Kurman et al 2000).
A blinded, randomized, controlled trial compared 
2 combinations of hormone therapy on occurrence of post-
menopausal uterine bleeding and endometrial histology. 
The investigators randomized 945 women for 12 months to 
E2/NETA(varying doses mg NETA/µg E2: 0/5, 0.25/5, 1/5, 
0/10, 0.5/10, 1/10) or to 0.625 mg conjugated equine estro-
gens (CEE)/2.5 mg medroxyprogesterone acetate (MPA). 
Endometrial sampling was performed at 0, 6, and 12 months 
of therapy. The investigators found that E2/NETA therapy 
had signiﬁ  cantly higher percentage of atrophic endometrium 
at 12 months compared with the CEE/MPA group (73% vs 
32%, respectively) (Portman et al 2003). Similar results 
have been obtained comparing continuous NETA vs MPA 
for contraceptive therapy and subsequent risk of developing 
endometrial cancer (OR = 1.07; 95% CI 0.86, 1.33 vs OR = 0.85 
95% CI 0.73, 0.98) (Weiderpass et al 1999).
Wells et al (2002) looked at the endometrial effects 
after long-term E2/NETA therapy. British women taking 
2 mg E2/1 mg NETA were followed for 5 years at 31 
clinics. Endometrial biopsies were obtained at 0, 9, and 
24–36 months of treatment. None of the 398 women com-
pleting the study had evidence of endometrial hyperplasia 
or malignancy. Interestingly, women with a previous 
diagnosis of complex hyperplasia prior to the initiation 
of therapy had normal endometrial biopsies at the end of 
treatment.
A randomized, double blind, multicenter study evalu-
ated 625 postmenopausal women with 3 doses of combined 
E2 and NETA compared to unopposed E2. Women were 
assigned to E2 50 µg per day or transdermal E2/NETA with 
50 µg E2 and 140, 250, or 400 µg of NETA. Endometrial 
biopsies were performed 12 months after treatment. Endo-
metrial hyperplasia was signiﬁ  cantly lower in the E2/NETA 
groups (Table 6) (Archer et al 1999).
Table 2 Intensity of hot ﬂ  ushes after 12 months of hormone 
therapy
Intensity of  E2 50 µg E2  50  µg/ E2  50  µg/ E2  50  µg/
hot ﬂ  ushes    NETA  NETA  NETA
   140  µg 200  µg 400  µg
Baseline 1.32  1.32  1.42  1.54
Endpoint 0.18  0.35  0.19  0.14
Table 3 Changes in bone mineral density after 2 years of E2/NETA 
therapy
 Total  Lumbar  Total  Femoral
  body spine femur  neck
Percentage  +2.9 (±2.4)  +6.9 (±4.2)  +3.4 (±3.6)  +4.0 (±3.4)
changeClinical Interventions in Aging 2008:3(1) 13
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Other physiologic effects
Memory and cognition
Longitudinal data from the Nurses Health Study and 
randomized clinical trial data from the Women’s Health 
Initiative have failed to show cognitive beneﬁ  ts with the use 
of postmenopausal hormonal therapy. Recently, Smith et al 
randomized patients to 5 µg E2/1 mg NETA or placebo and 
performed functional magnetic resonance imaging study. They 
found that hormonal therapy was associated with signiﬁ  cantly 
higher activation in the prefrontal cortex, an area of the brain 
critical in primary visual working memory, specifically 
monitoring, organization and planning (Smith et al 2006).
Cardiovascular disease
Cardiovascular disease is the leading cause of death among 
postmenopausal women, and unlike men, the death rate 
has remained relatively constant over the past 20 years. 
No randomized clinical trials have shown a benefit of 
postmenopausal hormone therapy for coronary heart disease 
as compared to placebo (ACOG Coronary Heart Disease 
Supplement 2004). Although most of these studies used 
different preparations of estrogen and progestin, one trial 
did use combination E2/NETA.
The Papworth HRT Atherosclerosis Study (PHASE) evalu-
ated 255 postmenopausal women with coronary artery disease 
who were randomly assigned to transdermal administration of 
17β-E2 if previous hysterectomy, 17β-E2 plus NETA if no pre-
vious hysterectomy or placebo. The primary endpoint included 
cardiac death, myocardial infarction, or hospital admission for 
unstable angina. There were 53 primary endpoint events in 
the hormone group and 37 events in the placebo group (HR 
1.29, 95% CI 0.84–1.95) (Clark et al 2002). More recently, 
it has been shown that coronary-artery calciﬁ  cation scores 
are lower among women receiving estrogen as compared to 
placebo (83.1 vs 123.1, respectively, p   0.02). The long term 
cardiovascular beneﬁ  t of estrogen on cardiovascular disease 
due to decreased arterial calciﬁ  cation has yet to be determined 
(Manson et al 2007). At this time, hormone replacement 
therapy cannot be recommended for primary or secondary 
prevention of cardiovascular disease.
Venous thromboembolic disease
Venous thromboembolic disease includes thrombosis of the 
retinal veins, deep veins of the legs, upper extremities or 
pulmonary arteries (ACOG Venous Thromboembolic Disease 
Supplement 2004). The risk of venous thromboembolic disease 
in women taking hormone therapy is 2-fold. A meta-analysis 
of 4 trials (Heart and Estrogen/Progestin Replacement Study, 
Estrogen in Venous Thromboembolism Trial, Women’s 
Estrogen for Stroke Trial and WHI) has shown relative risk 
of pulmonary embolism is increased (RR 2.16, 95% CI 
1.47–3.18). The PHASE trial, as described above reported 
2/134 thromboembolic events in the E2/NETA arm and 0/121 
events in the placebo arm (Clark et al 2002).
Stroke
Stroke is the third leading cause of death in the US. Eight 
randomized controlled trials have evaluated the rate of 
stroke in postmenopausal women and most have shown an 
increased risk of stroke with hormone replacement therapy 
(ACOG Stroke Supplement 2004). The WHI trial reported an 
increased risk in stroke (OR = 1.44, 95% CI 1.09, 1.90), how-
ever, different estrogen/progestin formulation was used. The 
PHASE trial, as previously described, reported 5/134 events 
of nonfatal stroke in the E2/NETA group and 3/121 events in 
placebo arm (OR = 1.50) (Clark et al 2002). At this time, it is 
unlikely whether the increased risk of stroke depends on the 
speciﬁ  c hormone preparation. Women should be counseled 
prior to the initiation of hormone therapy about the increased 
risk of stroke. Hormone therapy should be discontinued in 
anyone experiencing a cerebrovascular event.
Colorectal cancer
Colorectal cancer accounts for 11% of all cancer related 
deaths, and the age speciﬁ  c incidence for women aged 
50–54 years is 41.3 per 100,000 women (American Cancer 
Society 2003). To our knowledge, no investigators have 
Table 4 Changes in bone mineral density with E2/NETA vs 
alendronate
 Spine  Hip  Forearm  Total  body
2 mg E2/1 mg  +5.14%  +3.21%  +0.54%  +2.59%
NETA p    0.01  p   0.001    p   0.001
Alendronate  +3.34%  +1.60%  −1.14% 0.64%
Table 5 Incidence of endometrial hyperplasia with unopposed 
estrogen or combination norethindrone acetate/estradiol 
therapy
  E2 1 mg  E2 1 mg/  E2 1 mg/  E2 1 mg/
   NETA  NETA  NETA
    0.5 mg  0.25 mg  0.1 mg
Patients undergoing  247  241  251  249
endometrial biopsy
Patients with  36 (14.6%)  1 (0.4%)*  1 (0.4%)*  2 (0.8%)*
endometrial hyperplasia
*p   0.01Clinical Interventions in Aging 2008:3(1) 14
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reported the relative risk of colon cancer among women 
taking the specifically E2/NETA. However, the results 
of the WHI and several meta-analyses have reported a 
signiﬁ  cant reduction in the incidence of colorectal cancer in 
women taking combination hormone replacement therapy 
(RR 0.56, 95% CI 0.38–0.81). Several hypotheses exist on 
the protective mechanism of estrogen, which include the 
bile acid hypothesis, the estrogen receptor-β hypothesis 
and the gene-receptor hypothesis. Secondary bile acids are 
carcinogenic, and hormone therapy has shown to decrease 
bile acid synthesis (Grodstein et al 1999). Estrogen receptor-β 
expression has been shown to decrease colon cancer cell 
growth in vitro (Fiorelli et al 1999). Finally, the estrogen 
receptor gene may inactivate other gene expression and has 
been shown to suppress the growth of cancer cells in vitro 
and in vivo (Al-Azzawi and Whaab 2002).
Breast cancer
The association between estrogen and breast cancer was 
established well over 100 years ago (Beaston 1896). Risk 
factors for breast cancer include increased exposure to estro-
gen, such as early menarche, late full-term pregnancy and 
late menopause. Breast tissue can concentrate, metabolize 
and produce estrogen. Estrogen plays a role in the expression 
and transcription of growth factors and oncogenes (Verheul 
et al 2000). Progesterone is a mitogen in human breast cells 
and this cell proliferation may be the underlying process by 
which DNA damage occurs (Pike et al 1993). Data from the 
WHI showed that women who take hormone therapy are more 
likely to develop breast cancer than women who do not (HR 
1.24, 95% CI 1.01–1.54) (Rossouw et al 2002). Women should 
be counseled that the risk of breast cancer is increased with 
hormone therapy and dissipates when it is discontinued. A 
randomized trial (Hormonal Replacement Therapy after Breast 
Cancer – is it Safe?) investigated the effect of hormone therapy 
for women who were previously treated for breast cancer. 
The trial was discontinued because of a signiﬁ  cant increase 
in breast cancer events (HR 3.3, 95% CI 1.5–7.4) (Holmberg 
et al 2004). Alternatives to hormone therapy should be offered 
for women with a history of breast cancer.
Table 1 summarizes the risks and beneﬁ  ts of combination 
hormone therapy.
Side effects
The most common side effects of E2/NETA are uterine bleeding, 
headache, abdominal pain, and breast pain. Postmenopausal 
bleeding is a common side effect of hormone therapy, and is 
the most important factor determining whether postmenopausal 
women continue hormone therapy is uterine bleeding. Studies 
comparing bleeding proﬁ  les of different hormone therapy 
regimens are mixed. Johnson et al randomized women to 
E2/NETA or CEE/MPA to compare bleeding patterns. After 6 
months of therapy, amenorrhea was signiﬁ  cantly higher in the 
E2/NETA group (54.8%) than the CEE/MPA group (17.1%) 
(Johnson et al 2002), which paralleled previous ﬁ  ndings by 
Simon et al (2001). However, more recently Yildirim et al 
(2006) found no difference in bleeding patterns in women 
randomized to E2/NETA or CEE/MPA.
Rowan et al (2006) pooled 3 studies to determine the 
efﬁ  cacy and tolerability of NA/EE and found that amenorrhea 
and adverse side effects were similar to placebo (Table 7).
Table 7 Side effects of E2/NETA based on three randomized controlled trials
Study  Endometrial: hyperplasia  Vasomotor symptom  Osteoporosis
  12 months duration  study: 3 months  study: 24 months
Medication  1.0 mg E2/0.5 mg NETA  1.0 mg E2/0.5 mg NETA  1.0 mg E2/0.5 mg NETA
Duration of medication  12 months  3 months  24 months
Control group  Estradiol 1 mg  Placebo  Placebo
Side effect  E2/NETA  Estradiol  E2/NETA Placebo  E2/NETA  Placebo
Headache 16%  5%  3%  3%  6%  4%
Gastroenteritis  2% 2% 0%  0%  6%  4%
Nausea  3% 5% 10%  0%  11%  0%
Breast  pain  24% 10% 21%  0% 17%  8%
Table 6 Incidence of endometrial hyperplasia after treatment of 
unopposed E2 vs E2/NETA after one year of therapy
Medication E2  50  µg E2  50  µg/ E2  50  µg/ E2  50  µg/
   NETA  140  µg NETA  200  µg NETA  400  µg
Endometrial 37.9%  0.8%*  1%*  1.1%*
hyperplasia      *p    0.01
*p   0.01Clinical Interventions in Aging 2008:3(1) 15
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Continuation rates and cost-
effectiveness of E2/NETA
Simon et al (2003) compared continuation rates among 
women using 6 different hormone replacement therapies 
and found that patients prescribed 1 mg NETA/5 µg E2 were 
52% more likely to continue therapy than patients prescribed 
0.625 mg CEE/2.5 or 5 mg MPA.
Coyle et al (2003) compared the cost effectiveness and 
quality of life of E2/NETA and CEE/MPA. Measures of qual-
ity of life included presence and absence of vaginal bleeding, 
menopausal symptoms and hip fracture along with lifetime 
costs for a 50-year-old menopausal woman on therapy for 
5 years. This investigator concluded that E2/NETA is cost 
effective for women with menopausal symptoms (US$900/
quality adjusted life-years (QALY) gained for EE/NETA vs 
US$20,300/QALY gained for CEE/MPA).
Contraindications to hormone 
therapy
Table 8 lists contraindications to combination estradiol/
progestin therapy.
Conclusion
The goal of postmenopausal hormone therapy is to alleviate 
the symptoms that are associated with the loss of estrogen that 
women experience after menopause. Current indications for 
postmenopausal E2/NETA hormone therapy include treatment of 
severe vasomotor symptoms and prevention of postmenopausal 
osteoporosis; E2/NETA is likely equivalent to other hormonal 
preparations. Therapy should commence at the lowest effective 
dose and should be discontinued after the shortest duration pos-
sible. The choice of whether or not to begin therapy is ultimately 
the patient’s choice but also requires physicians providing care 
to postmenopausal women to effectively discuss the risks and 
beneﬁ  ts of estrogen and/or progestin replacement therapy.
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